ENTASIS THERAPEUTICS

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).

ENTASIS THERAPEUTICS

Social Links:

Twitter

Industry:

Biotechnology Health Care Medical Pharmaceutical

Founded:

2015-01-01

Address:

Waltham, Massachusetts, United States

Country:

United States

Website Url:

http://www.entasistx.com

Total Employee:

11+

Status:

Active

Contact:

(781)810-0120

Email Addresses:

[email protected]

Total Funding:

199.5 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome

Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

arrakis-therapeutics-logo

Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

celsius-therapeutics-logo

Celsius Therapeutics

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

centerline-biomedical-logo

Centerline Biomedical

Centerline Biomedical, a Cleveland Clinic spin-off, is developing an innovative system

cortexyme-logo

Cortexyme

Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.

dyne-therapeutics-logo

Dyne Therapeutics

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

editas-medicine-logo

Editas Medicine

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.

elicio-therapeutics-logo

Elicio Therapeutics

Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.

enlibrium-logo

Enlibrium

Enlibrium is a developing novel drugs

imtherapeutics-logo

IMTherapeutics

IM Therapeutics develops personalized immuno-therapeutic drugs.

phyla-logo

Phyla

Phyla is developing alternative therapies for antibiotics.

tiburio-therapeutics-logo

Tiburio Therapeutics

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.

vico-therapeutics-logo

Vico Therapeutics

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Current Advisors List

greg-norden_image

Greg Norden Board Member @ Entasis Therapeutics
Board_member
2016-10-01

david-hastings_image

David Hastings Board Member @ Entasis Therapeutics
Board_member
2018-04-01

heather-behanna_image

Heather Behanna Board Member @ Entasis Therapeutics
Board_member
2017-09-01

tracy-saxton_image

Tracy Saxton Board Member @ Entasis Therapeutics
Board_member

andy-staples_image

Andy Staples Board Member @ Entasis Therapeutics
Board_member
2015-05-01

david-meek_image

David Meek Chairman Of The Board @ Entasis Therapeutics
Board_member
2019-06-01

nicholas-galakatos_image

Nicholas Galakatos Board Chairman @ Entasis Therapeutics
Board_member
2016-03-01

manos-perros_image

Manos Perros Board Member @ Entasis Therapeutics
Board_member

Current Employees Featured

michael-gutch_image

Michael Gutch
Michael Gutch Chief Medical Officer @ Entasis Therapeutics
Chief Medical Officer

david-meek_image

David Meek
David Meek Chief Executive Officer @ Entasis Therapeutics
Chief Executive Officer
2021-09-01

john-mueller_image

John Mueller
John Mueller Chief Development Officer @ Entasis Therapeutics
Chief Development Officer
2016-07-01

john-mueller_image

John Mueller
John Mueller Vice President, Program Management & Early Development @ Entasis Therapeutics
Vice President, Program Management & Early Development
2015-05-01

matthew-ronsheim_image

Matthew Ronsheim
Matthew Ronsheim Chief Pharmaceutical Sciences & Manufacturing Officer @ Entasis Therapeutics
Chief Pharmaceutical Sciences & Manufacturing Officer

manos-perros_image

Manos Perros
Manos Perros Chief Executive Officer @ Entasis Therapeutics
Chief Executive Officer
2015-05-01

ruben-tommasi_image